The Investor Relations website contains information about TetraLogic Pharmaceuticals business for stockholders, potential investors, and financial analysts.
http://ir.tetralogicpharma.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.6 seconds
PAGES IN
THIS WEBSITE
12
SSL
EXTERNAL LINKS
51
SITE IP
206.200.251.19
LOAD TIME
0.563 sec
SCORE
6.2
Investor Relations - TetraLogic Pharmaceuticals | ir.tetralogicpharma.com Reviews
https://ir.tetralogicpharma.com
The Investor Relations website contains information about TetraLogic Pharmaceuticals business for stockholders, potential investors, and financial analysts.
ir.tetralogicpharma.com
Stock Chart | TetraLogic Pharmaceuticals Corporation Investor Center
http://ir.tetralogicpharma.com/stockquote.cfm
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Delayed at least 20 minutes. TetraLogic Pharmaceuticals, Inc. Sitemap. Legal Notice and Privacy Policy.
Events and Presentations | TetraLogic Pharmaceuticals Corporation Investor Center
http://ir.tetralogicpharma.com/events.cfm
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Delayed at least 20 minutes. There are no scheduled events at this time. Please check back later. TetraLogic Pharmaceuticals to Present at the 56th Annual American Society of Hematology Annual Meeting. Dec 7, 2014. Dec 8, 2014. TetraLogic Pharmaceuticals Investor Forum (Registration opens at 7:00 AM). Nov 10, 2014. TetraLogic Pharmaceuticals, Inc. Sitemap.
TetraLogic Pharmaceuticals Corporation Investor Center |
http://ir.tetralogicpharma.com/index.cfm
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Delayed at least 20 minutes. Birinapant is designed to mimic the activity of an endogenous protein, the Second Mitochondrial Activator of Caspases, or SMAC, which is involved in the regulation of the apoptotic process within cells. Avoidance of apoptosis is a critical step in cancer tumor development and certain infectious diseases. Nov 2, 2016. Jan 6, 2016.
Corporate Governance | TetraLogic Pharmaceuticals Corporation Investor Center
http://ir.tetralogicpharma.com/corporate-governance.cfm
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Delayed at least 20 minutes. Nominating and Governance Committee Charter. Code of Business Conduct and Ethics. TetraLogic Pharmaceuticals, Inc. Sitemap. Legal Notice and Privacy Policy.
Press Releases | TetraLogic Pharmaceuticals Corporation Investor Center
http://ir.tetralogicpharma.com/releases.cfm
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Delayed at least 20 minutes. Jan 6, 2016. TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs. Nov 9, 2015. TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting. Nov 4, 2015. Nov 2, 2015. Aug 5, 2015. Jul 29, 2015. Jul 29, 2015. Jul 20, 2015. Jun 30, 2015.
TOTAL PAGES IN THIS WEBSITE
12
Tetralogic Pharmaceuticals Birinapant
http://tetralogicpharma.com/birinapant
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Birinapant is a bivalent investigational SMAC mimetic. We believe that birinapant’s potential ability to inhibit the IAPs will block this suppression across multiple cancers and virally infected cells. When you...
Tetralogic Pharmaceuticals SHAPE
http://tetralogicpharma.com/shape
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. SHAPE’s composition of matter patent in the U.S. extends until at least 2028. In addition, SHAPE has been granted U.S. orphan drug designation for CTCL. We have acquired worldwide develo...When you click on the...
Tetralogic Pharmaceuticals Ovarian Cancer
http://tetralogicpharma.com/ovarian-cancer
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination with Conatumumab in Subjects with Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer. See all Clinical Trials. Rationale for treatment with birinapant administered with conatumumab. In pre cli...
Tetralogic Pharmaceuticals Management Team
http://tetralogicpharma.com/management-team
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. Richard L. Sherman, JD. Stephen M. Condon, PhD. Tony Meehan, PhD, MBA. Jeffrey Skolnik, MD. TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs. TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual[.]. Hepatitis: After HCV cure, HBV cure? You can also...
Tetralogic Pharmaceuticals News
http://tetralogicpharma.com/news-presentations
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. Presentations & Publications. TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs. TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual[.]. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.
Tetralogic Pharmaceuticals Cutaneous T-Cell Lymphoma (CTCL)
http://tetralogicpharma.com/cutaneous-t-cell-lymphoma-ctcl
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma. Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHAPE (SHP141) in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL). See all Clinical Trials. That me...
Tetralogic Pharmaceuticals Epigenetics
http://tetralogicpharma.com/epigenetics
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. TetraLogic Pharmaceuticals Corporation Sitemap. Legal Notice and Privacy Policy. NOTICE: You are leaving our website. When you click on the button below, you will leave our website and will enter a website main...
Tetralogic Pharmaceuticals Science
http://tetralogicpharma.com/science
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. TetraLogic Pharmaceuticals currently has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE). Legal Notice and Privacy Policy.
Tetralogic Pharmaceuticals About Us
http://www.tlog.com/about-us
SMAC Mimetics & Apoptosis. Birinapant Publications & Presentations. SHAPE Publications & Presentations. Cutaneous T-Cell Lymphoma (CTCL). Phase 1 Safety & Efficacy. Presentations & Publications. TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs. TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual[.]. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Is a histone deacetylase in...
TOTAL LINKS TO THIS WEBSITE
51
Investor Relations | TESARO, Inc.
Skip to main navigation. Strategic "Drug Hunting" Partnerships. Niraparib Expanded Access Program. Individual Compassionate Use Policy. Together, We Can Make a Difference. We are committed to serving the best interests of our shareholders. Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer. VIEW ALL PRESS RELEASES. Strategic "Drug Hunting" Partnerships.
Tesco Corporation - Investor Relations
Level III Inspections (annual). Major and Minor Repairs and Inspections. Certified Pre-Owned Top Drives. Compact Casing Drive System. Compact Casing Drive System. Onshore Casing and Tubing Handling. Automated Casing Running Services. Tubular Services Package Comparison. Offshore Casing and Tubing Handling. Deepwater Casing Running Solutions. Cementing and Casing Accessories. 04/07/17 4:00 pm ET. 160;- 0.05. Tesco Corporation to Present at the Scotia Howard Weil 45th Annual Energy Conference.
Introduction | Tesla Motors
Tuesday, January 3, 2017. Tesla Q4 2016 Production and Deliveries. Tuesday, November 15, 2016. Tesla Announces Special Meeting of Shareholders and Public Webcast. Monday, October 31, 2016. Question and Answer Webcast to Discuss Tesla's Pending Acquisition of SolarCity. Wednesday, October 26, 2016. Tesla Releases Third Quarter 2016 Financial Results. View all press releases. Jan 4, 2017. Tesla Gigafactory 1 Investor Event. File is in Briefcase. Nov 17, 2016. Tesla's Special Meeting of Shareholders.
Introduction | Tesla Motors
The Tesla Roadster entered production in 2008 and Model S in 2012. Deliveries for Model X coming in 2015. Wednesday, August 5, 2015. Tesla Releases Second Quarter 2015 Financial Results. Wednesday, July 22, 2015. Tesla Announces Release Date for Second Quarter 2015 Financial Results. Thursday, July 16, 2015. Tesla Invites America to Join the Next Billion. Thursday, July 2, 2015. Tesla Delivers 11,507 Vehicles in Q2 of 2015. View all press releases. Aug 5, 2015. Tesla Second Quarter 2015 Shareholder Letter.
Tessera | Investors
Tessera’s business operations include:. Pioneered chip-scale packaging solutions, which it licenses to the semiconductor industry. Develops and acquires interconnect solutions and intellectual property in areas such as mobile computing and communications, memory and data storage, and 3-D integrated circuit technologies. Tessera Intellectual Property Corp. Manages our intellectual property licensing efforts, including for Tessera, Inc. and Invensas. Aug 3, 2015. Jul 21, 2015. Aug 3, 2015 at 5:00 PM ET.
Investor Relations - TetraLogic Pharmaceuticals
SMAC Mimetics and Apoptosis. Birinipant Publications and Presentations. SHAPE Publications and Presentations. Cutaneous T-Cell Lymphoma (CTCL). Day Range: 2.48 - 1.45. Year Range: 6.30 - 1.45. 4:00 PM ET on Aug 17, 2015. Delayed at least 20 minutes. SHAPE is a histone deacetylase inhibitor, or HDACi. Altered expression of histone deacetylases, or HDACs, has been linked to tumor development and several drugs approved for systemic use in the treatment of cancers take advantage of this mechanism. Aug 5, 2015.
Teva pharmaceutical Industries | Investor Relations | Investor Relations
Your browser does not support iframes. See Teva's sites around the world. USA and its Territories. Japan and S. Korea. Want to find out more about Teva's locations and phone numbers? National Network of Excellence. Over the Counter (OTC). Central Nervous System (CNS). Inspiring Change for Women in Japan. PLIVA Awarded Two Golden Keys. Grow with the Best. Associate Director, Global Marketing. Teva and Immuneering Announce Teva’s Purchase of 51% Equity Share of Genomic-Analysis Company. Teva Pharmaceutical...
Investor Relations | Beneficial Bank
Beneficial Equipment Finance Corp. 4:00 PM ET on Mar 29, 2018. Delayed at least 20 minutes. Beneficial Bancorp, Inc. Announces Quarter and Year End Results and Cash Dividend to Shareholders. Quality information for our shareholders. 1555 -0.10 (-0.639%). February 13, 2018 Beneficial Bancorp Investor Presentation. November 7, 2017 Beneficial Bancorp Investor Presentation. April 20, 2017. Beneficial Bancorp Shareholder Presentation. March 28, 2017. Beneficial Bancorp Investor Presentation. November 17, 2016.
The Coca-Cola Company: Reports and Financial Information
160; 0.15. Aug 07, 2015 4:00 pm ET. 2014 Annual Report on Form 10-K. Second Quarter 2015 Earnings Release. First Quarter 2015 Form 10-Q. Data provided by Nasdaq. Minimum 15 minutes delayed.
thedispensingsolution.com
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Fortress International Group Inc. - Investor Relations
Error Page cannot be displayed. Please contact your service provider for more details. (18).
SOCIAL ENGAGEMENT